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4Abstract
Background information
RhoGTPases are involved in many biological processes and participate in cancer
development. Their activation is catalyzed by exchange factors (RhoGEFs) of the Dbl
family. RhoGEFs display proto-oncogenic features, thus appearing as candidate
targets for anticancer drugs. Dominant negative RhoGTPase mutants have been
widely used to block RhoGEF signaling. However, these tools suffer from limitations,
due to the high number of RhoGEFs and the complex mechanisms that control
RhoGTPase activation.
Results
RhoG-T17N is a poor inhibitor of its exchange factor TRIO-GEFD1 in vivo: although it
binds to TRIO-GEFD1, RhoG-T17N does not block the downstream signaling. Using
the Yeast Exchange Assay we show that in the presence of TRIO-GEFD1, RhoG-
T17N can bind to its effectors, which illustrates how negative mutants may produce
misleading interpretations and emphasizes the need of new types of RhoGEF
inhibitors. In that prospect, we adapted the Yeast Exchange Assay method to identify
RhoGEF inhibitors. Using this novel approach, we screened a 3,500 chemical
compound library and identified a potential inhibitor of TRIO-GEFD1. This molecule
inhibited TRIO-GEFD1 in vitro. Among the chemical analogs of this compound, we
identified two molecules with better inhibitory activity. The three TRIO-GEFD1
inhibitors had no effect on ARHGEF17 and ARNO, two exchange factors for RhoA
and Arf1 respectively.
Conclusions
The development of RhoGEF inhibitors appears as a necessary tool for the study of
Rho GTPase signaling pathways. The Yeast Exchange Assay adaptation we present
5here is suitable to screen for chemical or peptide libraries and identify candidate
inhibitors.
61- Introduction.
Small GTPases of the Rho family regulate actin cytoskeleton dynamics, cell
morphology, adhesion, migration, intracellular trafficking, embryonic development,
apoptosis and transformation (Etienne-Manneville and Hall, 2002). They are inactive
when bound to GDP and active when bound to GTP. When active, they can bind to
their effectors and activate downstream signaling cascades. Rho GTPase activation
is catalyzed by Guanine Nucleotide Exchange Factors (GEFs) of the Dbl and the
CZH/DOCK families. In mammals, there are 65 Dbl-related (Rossman et al., 2005)
and 11 DOCK-related proteins (Meller et al., 2005) and each GEF activates one or
several GTPases. The exchange domain is responsible for GTPase activation.
RhoGEFs contain additional domains involved in lipid and protein binding that are
supposed to regulate their localization and biological activity.
The interaction between the GTPase and the exchange factor is a complex
mechanism involving multiple domains of either partner. Even though several three-
dimensional structures of GTPase-GEF complexes have been solved, the exact
mechanisms of substrate selectivity by the exchange factors are not known (Erickson
and Cerione, 2004; Rossman et al., 2005). Mutant analyses revealed that point
mutations at identical positions could have distinct effects depending on the GTPase
and the exchange factor involved. For instance, the T37A mutant of RhoA and the
equivalent T35A mutant of Cdc42 do not respond to activation by their respective
exchange factors Lbc and Cdc24 (Li et al., 1997). In contrast, the T35A mutant of
Rac1 still responds to TRIO-GEFD1 (Gao et al., 2001). Similarly, while the F39E
mutant of RhoA cannot be activated by Lbc, it retains the ability to be activated by
Dbl (Li and Zheng, 1997). In that context, the development of RhoGEF specific
inhibitors would be valuable tools to decipher RhoGTPase signaling pathways.
7As suspected for a long time (Ron et al., 1988), Dbl proteins are involved in
various human pathologies including cancer (Kanekura et al., 2004; Orrico et al.,
2004). Abnormal exchange factor function was described in various pathologies
(Ridley, 2004) in particular due to their oncogenic potential (Karnoub et al., 2004).
Therefore, components of RhoGTPase signaling pathways appear as potential
anticancer therapeutic targets (Sahai and Marshall, 2002). RhoGTPases have a wide
range of tissue distribution, participate in different signaling cascades and can be
activated by several exchange factors in the same cell. In contrast, Rho GEFs have a
narrower tissue distribution and are activated downstream of specific membrane
receptors (Zheng, 2001). Thus, beside their applications for the study of RhoGTPase
signaling pathways, RhoGEF inhibitors would also be of major interest to develop
new drugs.
Much effort is being made to isolate RhoGEF inhibitors and the interface
between the GTPase and the exchange factor may be an interesting target site
(Aznar and Lacal, 2001; Ramirez De Molina et al., 2001). Nevertheless, only one
RhoGEF specific inhibitor was isolated so far: the peptide TRIPα, which inhibits
RhoA activation mediated by TRIO-GEFD2, the second exchange domain of TRIO
(Schmidt et al., 2002). TRIPα was initially isolated in a two-hybrid screen of a random
peptide library according to its ability to bind TRIO-GEFD2 (Schmidt et al., 2002).
Structural analyses of the interface between the GTPase and the exchange factor
can also help for the design of specific interactors by in silico docking (Cherfils, 2001;
Erickson and Cerione, 2004). Applying such structure-based virtual screening
approach, a specific inhibitor of Rac activation was identified that targets the
RhoGEF recognition groove of the GTPase (Gao et al., 2004).
8We previously reported the Yeast Exchange Assay, a rapid qualitative test to perform
wide range screens for GEF specificity (De Toledo et al., 2000). Here we present a
novel method based on the Yeast Exchange Assay, which is suitable to perform
screens for chemical or peptide inhibitors of GEF activity. To illustrate this
application, we present a screen of a library of chemical compounds and the
identification of an inhibitor of TRIO-GEFD1, the first exchange domain of TRIO that
is an activator of RhoG (Blangy et al., 2000).
92- Results.
2.1- RhoG-T17N does not act as a dominant negative to inhibit TRIO-
GEFD1.
Based on early studies on Ras proteins, the negative T17N mutation is thought
to generate a nucleotide-free GTPase that is expected to have a high binding affinity
for the exchange factor and thereby to function as a dominant negative mutant
(Farnsworth and Feig, 1991; Feig and Cooper, 1988a; Feig and Cooper, 1988b).
Accordingly, two hybrid experiments showed that RhoG-T17N bound efficiently to its
exchange factor TRIO-GEFD1(Blangy et al., 2000), whereas it did not bind to the
RhoA and RhoC exchange factor TRIO-GEFD2 (Figure 1A). When expressed in
REF-52 cells, TRIO-GEFD1 induced the formation of lamellipodia and dorsal ruffles
(Figure 1B, a-b) characteristic of RhoG activity (Blangy et al., 2000; Vignal et al.,
2001). Surprisingly, RhoG-T17N did not inhibit TRIO-GEFD1 induced actin
remodeling (Figure 1B, c-e). RhoG-T17N and TRIO-GEFD1 appeared to colocalize in
the regions of actin polymerization, in dorsal ruffles and at the leading edge of the
cell (arrow in Figure 1B, panels c-e). These results suggest that the two proteins can
also interact in fibroblasts but that RhoG-T17N does not act as a competitive
dominant negative inhibitor of the exchange factor TRIO-GEFD1. Substitution of
D118, another conserved residue among Rho GTPases, also generates a nucleotide
binding deficient GTPase as shown for Cdc42 (Tu et al., 2002). According to
previous observations (Blangy et al., 2000), RhoG-D118A efficiently inhibited TRIO-
GEFD1 induced lamellipodia and dorsal ruffles formation (Figure 1B, f-h). Contrarily
to RhoG-T17N, RhoG-D118A acted as a dominant negative mutant on TRIO-GEFD1,
as shown by the inhibition of actin remodeling. RhoG-T17N thus has an unexpected
activity towards TRIO-GEFD1.
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To get a better understanding of these observations in REF-52 cells, we further
studied RhoG-T17N and RhoG-D118A in the Yeast Exchange Assay (De Toledo et
al., 2000), a GEF assay based on the two hybrid system (Figure 1C, a). Kinectin is a
known effector of RhoG (Vignal et al., 2001). When expressed in yeast, RhoG-wt, -
T17N or -D118A did not bind to kinectin (Figure 1C, b). The further expression of
TRIO-GEFD1 promoted the binding of RhoG-wt to kinectin as reported earlier (De
Toledo et al., 2000). Unexpectedly, RhoG-T17N also bound to kinectin when TRIO-
GEFD1 was expressed, whereas RhoG-D118A did not (Figure 1C, b). The binding of
RhoG-T17N to kinectin was not observed when TRIO-GEFD2 (Figure 1C, b). Similar
results were obtained using two other RhoG effectors unrelated to kinectin (Vignal et
al., 2001): the RabGAP RhoGIP56/AS160 (Kane et al., 2002; Larance et al., 2005)
and the TRAF3 interacting protein RhoGIP122/T3JAM (Dadgostar et al., 2003;
Vigorito et al., 2004), showing that this observation is not restricted to kinectin (our
unpublished observations). As TRIO-GEFD1 did not interact directly with kinectin
(Figure 1D), these results show that RhoG-T17N can bind to its effectors when the
exchange factor TRIO-GEFD1 is expressed.
These observations in yeast are consistent with the results in REF-52 cells and
suggest that RhoG-T17N is not an efficient inhibitor of TRIO-GEFD1.
2.2 Establishment of a GEF inhibitor screening method based on the
Yeast Exchange Assay.
To identify RhoGEF inhibitors, we took advantage of the Yeast Exchange
Assay. We speculated that in this system we could measure the inhibition of GEF
activity by adding a chemical compound or a peptide as a fourth partner (Figure 2A).
The only RhoGEF inhibitor described so far is the peptide TRIPα  that binds to and
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inhibits TRIO-GEFD2 (Schmidt et al., 2002). In yeast, TRIO-GEFD2 activated RhoC
and promoted its binding to its effector ROCK (Figure 2B, a). When TRIPα was
expressed as a fourth partner, the binding of RhoC to ROCK was lost (Figure 2B, b).
This indicates that TRIPα can inhibit TRIO-GEFD2 activity in yeast. Moreover,
TRIPα expression did not affect RhoC activation by another exchange factor:
ARHGEF17 (De Toledo et al., 2000), showing that the peptide is also specific for
TRIO-GEFD2 in this assay (Figure 2B). Thus, the Yeast Exchange Assay appears as
an appropriate method to screen libraries and identify directly peptides or chemical
compounds that interfere with GEF exchange activity.
Yeast has long been regarded as a tempting system to screen for drugs, in
particular inhibitors of protein-protein interaction (Vidal and Endoh, 1999). To
increase the screening sensitivity for Rho GEF inhibitors, we modified the TAT7
strain to make it permeable to a wider range of chemical compounds including
hydrophilic or charged molecules. For that purpose, we inserted a Kanamycin
resistance cassette into the erg6 gene. Disruption of erg6, which encodes a
methyltransferase in the ergosterol biosynthetic pathway, is not lethal in
Saccharomyces cerevisiae. The disruption affects ergosterol synthesis and
membrane function, erg6 deficient yeasts being more sensitive to a broad range of
compounds among which BrefeldinA, the inhibitor of the ARF GTPase exchange
factor Sec7 (Chardin and McCormick, 1999; Shah and Klausner, 1993; Vogel et al.,
1993). To verify that erg6 disruption was efficient in the context of the Yeast
Exchange Assay, RhoG-wt, Kinectin and TRIO-GEFD1 were expressed in both
erg6+ and erg6- yeasts. Cell permeabilization in liquid nitrogen confirmed that ß-
galactosidase expression induced by TRIO-GEFD1 expression was similar in both
yeast strains (Figure 2C, a). We then compared yeast permeability by plating both
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strains on X-gal supplemented medium. Whereas the unmodified TAT7 strain
remained white (Figure 2C, b: ERG6+), the strain in which erg6 was disrupted readily
turned blue (Figure 2C, b: ERG6-), indicating that the disruption of erg6 helped X-gal
entry in yeast.
The disruption of erg6 is compatible with the study of RhoGEF activity in the
Yeast Exchange Assay. Moreover, such mutation may facilitate the entry of a wider
range of chemical compounds in yeast.
2.3- Identification of chemical inhibitors of TRIO-GEFD1.
In order to identify potential TRIO-GEFD1 inhibitors we developed a two-step
procedure combining yeast and in vitro exchange assays. We first used the erg6 -
strain expressing RhoG-wt, Kinectin and TRIO-GEFD1 to screen a series of 3,500
chemicals (see Materials and Methods). Compounds were selected for their ability to
inhibit growth in selective HIS- medium, indicative of the inhibition of GTPase
activation, and having no effect on growth in non-selective HIS+ medium, to discard
cytotoxic drugs. Such molecules are candidate inhibitors of TRIO-GEFD1 mediated
RhoG activation (Figure 2A). We further tested the selected compounds for their
ability to inhibit TRIO-GEFD1 catalyzed nucleotide release by RhoG in vitro, using
[3H]-GDP dissociation assays with purified recombinant proteins.
Through this procedure, we selected 1-(3-nitrophenyl)-1H-pyrrole-2,5-dione
(C10H6N2O4, NPPD, Figure 3A) as a potential TRIO-GEFD1 inhibitor, which was
then analyzed in vitro in more details. [3H]-GDP dissociation assays showed that pre-
incubation of TRIO-GEFD1 with NPPD significantly reduced its activity on RhoG, the
longer the preincubation, the higher the inhibition (Figure 3B). Preincubation of the
inhibitor with the GTPase did not increase its inhibitory activity (our unpublished
data). NPPD inhibition was dose dependent. Nucleotide exchange was reduced from
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70% down to 55% in the presence of 50 µM NPPD and to only 35% in the presence
of 100 µM inhibitor (Figure 3C). Finally, kinetic analysis confirmed that NPPD
significantly slowed down the nucleotide exchange reaction catalyzed by TRIO-
GEFD1 (Figure 3D). These results show that NPPD can function as an inhibitor of
TRIO-GEFD1 in vitro.
To identify more potent inhibitors, we tested a series of 23 NPPD structural
analogs. We measured the initial exchange rate using N-methylanthraniloyl (Mant)-
GTP as a fluorescent readout (Hemsath and Ahmadian, 2005). Among the molecules
tested two were more efficient inhibitors than NPPD: 1,1'-(1,2-phenylene)bis(1H-
pyrrole-2,5-dione) (C14H8N2O4, PEPD, Figure 4A, a) and 1,1'-(2-chloro-1,4-
phenylene)bis(1H-pyrrole-2,5-dione) (C14H7ClN2O4, CPEPD, Figure 4A, b). At a
concentration of 100 µM, corresponding to a 1000 fold molar excess compared to the
exchange factor, NPPD reduced the initial exchange rate by 48.7%, PEPD and
CPEPD inhibited the initial exchange rate by 92.4 and 99.8% respectively (Figure 4B,
a-d). Dose response experiments confirmed that PEPD and CPEPD were more
efficient than NPPD at inhibiting TRIO-GEFD1 catalyzed nucleotide exchange by
RhoG (Figure 4B, a-d): the IC50 of the compounds were 115.5 µM for NPPD, 55.8 µM
for CPEPD and 51 µM for PEPD (Figure 4B, d). Of the other analogs of NPPD
tested, 10 compounds had a similar inhibitory activity on TRIO-GEFD1 as NPPD and
11 compounds had not effect on the exchange reaction (our unpublished
observations).
In the absence of TRIO-GEFD1, Mant-GTP remained stably bound to RhoG in
the presence of NPPD, CPEPD or PEPD (Figure 5A, a, b and c respectively)
showing that these compounds did not affect the stability of nucleotide binding to
RhoG. We finally studied the specificity of the inhibitors. We tested the effects of
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NPPD, PEPD and CPEPD on nucleotide exchange by RhoA catalyzed by
ARHGEF17 (Figure 5B, a, b and c respectively) (De Toledo et al., 2000) and by Arf1
catalyzed by ARNO (Figure 5C, a, b and c respectively) (Antonny et al., 1997).  In the
presence of a 1000 fold molar excess of NPPD (a), CPEPD (b) and PEPD (c) as
compared to the exchange factor, the Mant-GTP exchange reactions catalyzed by
ARHGEF17 and ARNO were not or slightly inhibited (Figure 5D), as compared to the
inhibition of TRIO-GEFD1 by these compounds (Figure 4B, d).
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3- Discussion
In this report we show that RhoG-T17N does not inhibit its exchange factor
TRIO-GEFD1, which illustrates the limitation of using dominant negative
RhoGTPases as inhibitors. In order to develop new tools to study RhoGTPase
signaling, we developed a novel strategy derived from the Yeast Exchange Assay to
screen for inhibitors of exchange factor mediated GTPase activation. Using this
approach we further present the screening of a chemical compound library and the
identification three chemical inhibitors of TRIO-GEFD1.
Rho GTPases mutants such as Rac1-T17N and Cdc42-T17N have been widely
used to inhibit the downstream signaling of exchange factors in vivo. Based on
original studies on Ras, these mutants are expected to function by sequestering the
exchange factors away from the endogenous GTPase. Several examples do support
this model: for instance, expression of Rac1-T17N inhibits membrane ruffling induced
by TIAM-1 overexpression (Michiels et al., 1995) and Cdc42-T17N inhibits p38 MAP
kinase activation induced  by ßPIX overexpression (Lee et al., 2001). Nevertheless,
some RhoGTPase T17N mutants may retain the ability to bind their effectors and
activate downstream signaling pathways in the presence of an exchange factor, as
we illustrate here in the case of RhoG-T17N. This suggests that the stable binding to
TRIO-GEFD1 may induce conformational changes allowing RhoG-T17N to bind to its
effectors. These observations further support the hypothesis that the binding of the
GTPase to the effector may occur within a three partner complex also involving the
exchange factor, as suggested for the Dbl, Cdc42 and PAK1 (Wang et al., 2004).
This mechanism should participate to the spatial regulation of signaling cascade
activation in the cell. We show here that in the presence of TRIO-GEFD1, RhoG-
T17N can bind to its effector, whereas Cdc42-wt but not T17N can form a complex
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with Dbl and PAK1 (Wang et al., 2004). Thus, the T17N mutation may not be
equivalent in all RhoGTPases; furthermore, a T17N GTPase may also behave
distinctly towards its different GEFs, as reported earlier for other point mutations
(Gao et al., 2001; Li et al., 1997; Li and Zheng, 1997). The use of dominant negative
mutants also suffers further limitations such as the occurrence of gain of function
phenotypes, as shown recently for Cdc42-T17N (Czuchra et al., 2005) and specificity
towards the exchange factor. Rho GTPase signaling involves 18 small GTPases and
more than 80 RhoGEFs in mammals (Meller et al., 2005; Rossman et al., 2005). Rho
GTPases share more than 55% homology and several RhoGEFs can activate each
GTPase. Thus Rho GTPase mutants may be non-discriminative between exchange
factors and interfere non-specifically with signaling cascades. In that context, detailed
analysis of the complex Rho signaling pathways requires the development of new
tools such as specific RhoGEF inhibitors.
We have developed an approach based on the Yeast Exchange Assay, which
allows the direct screening of peptide or chemical compounds that inhibit the
exchange reaction. We have disrupted the erg6 gene to render yeast sensitive to a
wider range of chemical compounds. The disruption is also convenient when
performing peptide library screening as it helps rapid identification of interesting
peptides: upon plating ERG6 deficient yeasts on X-gal plates, colonies turn blue
when the exchange factor is active and stay white when a peptide is expressed that
inhibits the exchange reaction. Using this screening procedure, we identified NPPD
as a potential inhibitor of TRIO-GEFD1. We confirmed that NPPD inhibits TRIO-
GEFD1 catalyzed nucleotide exchange by RhoG in vitro. Among chemical analogs of
NPPD, we identified CPEPD and PEPD as more efficient inhibitors of TRIO-GEFD1.
These compounds did not affect the stability of guanine nucleotide binding on RhoG
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and were able to discriminate between GTPases and exchange factors. Therefore,
they appear as good inhibitors of TRIO-GEFD1. We tested a series of 23 analogs of
NPPD. The analysis of the active and inactive compounds suggests that the 1-
(phenyl)-1H-pyrrole-2,5-dione structure is necessary to obtain efficient inhibition of
TRIO-GEFD1. Substitutions of small groups at position 4 of the phenyl do not affect
inhibition while bigger groups lead to compounds unable to inhibit the exchange
reaction. Nevertheless, only 24 compounds were tested and more combinatorial
chemistry analyses should be performed to delineate the active backbone and
optimize the structures of NPPD, CPEPD and PEPD and further improve their
inhibitory effect. Chemical analysis would also be necessary to design molecules with
improved solubility and chemical stability.
In conclusion, these results show that the Yeast Exchange Assay is well
adapted for high throughput screens of Rho GEF inhibitors and a valuable tool to
provide candidate molecules for further studies. Such inhibitors would be most
valuable for the study of RhoGTPase signaling pathways and may also have further
therapeutic applications.
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4- Materials and methods
4-1 Plasmids, yeast strain constructs transformation and growth.
The aptamer TRIPα fused to thioredoxin and thioredoxin alone (Schmidt et al.,
2002) were fused to the myc tag and inserted with p25MET promoter in pRs422
plasmid that contains the ADE2 selection marker. Arf1 and ARNO proteins were a
gift from Bernard Guibert and Jean-Christophe Zeeh, Gif sur Yvette, France. Other
yeast, bacteria and cell expression vectors were described earlier (Blangy et al.,
2000; De Toledo et al., 2000; Vignal et al., 2001). Yeasts were transformed with LiAc
using standard protocols (De Toledo et al., 2000). Yeasts were grown in complete
YDP medium or minimal SD medium supplemented with the appropriate aminoacids
and containing 0.1 M glucose. For inhibitor screen, yeasts were grown in 96 well
plates in selective His- medium containing 2 mM 3-AT, 2% DMSO and 0.2 mM
inhibitor. Each plate was done in duplicate and yeast growth was measured at OD570.
All chemical compounds were purchased from ChemBridge (San Diego, CA, USA).
The disruption of erg6 gene by insertion of a kanamycin resistance cassette
was amplified from strain Y00568 (erg6, isogenic to BY4741 with YML008c::kanMX4,
a gift from Matthias Peter, Zurich, Switzerland) with the following primers: UPERG6
5 ' -GCTGTTGCCGATAACTTCTTCATTGC-3 '  and DWNERG6 5 ' -
CTGATAGAAAATACTGGTCGTTTGCCACG-3', using Platinium Taq Polymerase
High Fidelity (Invitrogen). The PCR fragment was then transformed into TAT7 and
transformants were selected on plates containing 200 µg/ml G418. Disruption of erg6
gene by homologous recombination was verified by PCR on genomic yeast DNA
using primers in erg6 located upstream and downstream UPERG6 and DWNERG6,
respectively: UPUPERG6 5'-CGAAGATTGGTGAGAAACCTC-3' and
DWNDWNERG6 5'-GTCAATACGTTTGTATGCAGTG-3' as well as primers in the
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kanamycin resistance cassette: KAN787 5'-TTGCCATCCTATGGAACTGC-3' and
KAN1023 5'-ACGACTGAATCCGGTGAGAA-3'.
4.2 Cell lines, transfection and immunofluorescence.
Rat embryo fibroblasts (REF-52) were cultured at 37°C in the presence of 5%
CO2 in DMEM supplemented with 10% fetal calf serum as described (Blangy et al.,
2000). Cells were plated on 12 mm glass coverslips 16-24 hours before being
transfected using the lipofectamine method as described by the supplier (Invitrogen).
4 hours after transfection, the medium was changed, cells were fixed 20 hours later
for 10 minutes in 3.7% formalin in PBS. After a 2 minute permeabilization in 0.1%
Triton X-100 in PBS and a 30 minute incubation in 0.1% BSA in PBS, cells were
processed for immunofluorescence. Expression of myc-epitope tagged proteins was
visualized after incubation with the 9E10 anti-myc monoclonal antibody followed by
incubation with biotin conjugated sheep anti mouse IgG (1/200 dilution, Amersham)
and then with in streptavidin texas red (1/200 dilution, Amersham). Cells were
stained for actin using amino-methyl coumarin (AMCA)-conjugated phalloidin (0.5
U/ml, Sigma). Cells were washed in PBS and mounted in Mowviol (Aldrich) and
observed using a DMR Leica microscope with a 63x planochromat lens. Images were
recorded using a Hamamatsu CCD camera, transferred to Adobe Photoshop.
Transfections were repeated at least three times and an average of 100 cells were
examined.
4.3 Radioactivity and fluorescence -based guanine nucleotide exchange
assays.
GST-fused GTPases and exchange factors were expressed in E. coli, purified
on glutathione-S-Sepharose 4B beads (Amersham) as described previously (Blangy
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et al., 2000; De Toledo et al., 2000). Recombinant Arf1 and ARNO (Antonny et al.,
1997) were purified as described (Beraud-Dufour et al., 1998).
Radioactivity based guanine nucleotide exchange assays were performed as
described (Blangy et al., 2000; De Toledo et al., 2000). Briefly, 0.3 µM [3H]GDP-
loaded RhoG was mixed with 1 mM GTP and 0.1 µM TRIO-GEFD1 in exchange
buffer (50 mM Tris pH7.5, 2 mM MgCl2) containing 5% DMSO and the inhibitor at the
desired concentration. Reactions were performed at 20°C. At appropriate time points,
reaction was stopped with 50 mM Tris pH7.5, 10 mM MgCl2 and the amount of
[3H]GDP-loaded RhoG was determined by filtration on 0.2 µm nitrocellulose as
described (Blangy et al., 2000). The GEF activities were presented as radioactivity
bound to RhoG relative to samples without GEF defined as 100%.
Fluorescence based guanine nucleotide exchange assays were performed using N-
methylanthraniloyl (mant)-GTP (Molecular Probes) in a FLX800 microplate
fluorescence reader (BIO-TEK Instruments) at 25°C. Exchange assays containing
0.1 µM GEF were incubated for 30 minutes in reaction buffer (20 mM Tris-HCl pH7.5,
50 mM NaCl, 2 mM MgCl2, 1 µM Mant-GTP and 50 µg/ml BSA) containing 5%
DMSO and the inhibitor at the desired concentration. The exchange reaction was
started by addition of 1µM GTPase. The relative Mant fluorescence (excitation = 360
nm, emission = 460 nm) was monitored for 10 minutes and measurements were
taken every 10 seconds. The rates (kobs) of guanine nucleotide exchange were
determined by fitting the data as single exponential association or decay equations
using Graphpad Prism 4 as described (Rossman et al., 2003).
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Figure legends
Figure 1: RhoG-T17N mutant does not inhibit the exchange factor TRIO-
GEFD1. A: Two-hybrid protein interactions. Interaction between RhoG-wt, -G12V or -
T17N fused to LexA DNA binding domain (LexA) and TRIO-GEFD1 (GEFD1, aa
1232-1429), TRIO-GEFD2 (GEFD2, aa 1849-2450) or Kinectin (aa 630-935) fused to
GAL4 activation domain (GAL-AD) was visualized in TAT7 by monitoring the lacZ
reporter gene expression using a filter assay for ß-galactosidase activity. B: Effects
of RhoG-T17N and -D118A on TRIO-GEFD1 induced actin reorganization. REF-52
cells expressing myc tagged TRIO-GEFD1 alone (a and b) or with GFP tagged
RhoG-T17N (c-e) or -D118A (f-h) were processed for detection of myc epitope (a and
d), GFP fluorescence (c) and filamentous actin (b and e). Bar in b, 10 µM. C: Yeast
Exchange Assay. (a) Principle of the yeast exchange assay (De Toledo et al., 2000).
Wild type GTPase does not bind to its effector and the ß-galactosidase reporter gene
is not expressed unless a specific GEF is expressed (b) ß-galactosidase activity in
TAT7 expressing RhoG-wt, -T17N, -D118A or -G12V fused to LexA DNA binding
domain, Kinectin RhoG binding domain fused to GAL4 activation domain and no
exchange factor (none) or myc tagged TRIO-GEFD1 (GEFD1) or TRIO-GEFD2
(GEFD2). D: Two-hybrid protein interactions performed as in A. Interaction between
RhoG-T17N and kinectin fused to LexA DNA binding domain (LexA) and TRIO-
GEFD1  or Kinectin (aa 630-935) fused to GAL4 activation domain (GAL-AD)
Figure 2: Adaptations of the Yeast Exchange Assay to isolate Rho GEF
inhibitors. A: Principle of the GEF inhibitor detection system based on the Yeast
Exchange Assay. Wild type GTPase does not bind to its effector and reporter genes
are not expressed (a) unless a specific GEF is expressed (b). Addition of a peptide or
a chemical compound that inhibit the GEF results in GTPase inactivation and the lack
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of expression of the reporter genes (c). B: Specific inhibition of TRIO-GEFD2 by the
TRIPα peptide in the Yeast Exchange Assay. ß-galactosidase activity in TAT7
expressing RhoC-wt fused to LexA DNA binding domain, GAL4 activation domain
fused to ROCK, no GEF (none) or myc tagged TRIO-GEFD2 or ARHGEF17 and myc
tagged thioredoxin (a: - TRIPα) or thioredoxin fused to TRIPα (b: + TRIPα). C: The
disruption of erg6 allows X-gal entry into yeast. Detection of ß-galactosidase activity
with a filter assay after yeast breakage with liquid nitrogen (a) or directly on X-gal
containing plates (b) in TAT7 yeast bearing the erg6 gene disruption (ERG6-) or not
(ERG6+) and expressing RhoG-wt fused to LexA DNA binding domain, GAL4
activation domain fused Kinectin and no GEF (none) or myc tagged TRIO-GEFD1.
Figure 3: Characterization of 1-(3-nitrophenyl)-1H-pyrrole-2,5-dione as a
TRIO-GEFD1 inhibitor. In vitro exchange assays were performed by measuring the
decrease with time of radioactivity associated with RhoG. The data shown are
representative of three individual experiments. Means and SEM are shown for
duplicate measures.  A: Structure of 1-(3-nitrophenyl)-1H-pyrrole-2,5-dione (NPPD),
B: 0.1 µM TRIO-GEFD1 (GEFD1) was incubated for 30 minutes in exchange buffer
with 5% DMSO or for 30, 15 or 5 minutes in 5% DMSO containing 100 µM NPPD. 0.3
µM [3H]-GDP loaded RhoG and 1 mM GTP were then added and the amount of
radioactivity associated with the GTPase was measured after 15 minutes. 100% was
determined by incubating [3H]-GDP loaded RhoG alone in exchange buffer
containing 1 mM GTP and 5% DMSO for 15 minutes (-GEF). C: 0.1 µM TRIO-
GEFD1 (GEFD1) was incubated for 30 minutes in exchange buffer containing 5%
DMSO alone or with 50 µM or 100 µM NPPD. 0.3 µM [3H]-GDP loaded RhoG and 1
mM GTP were then added and the amount of radioactivity associated with RhoG was
measured after 5 minutes. 100% was determined by incubating [3H]-GDP loaded
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RhoG alone in exchange buffer containing 1 mM GTP and 5% DMSO for 5 minutes (-
GEF). D: 0.1 µM TRIO-GEFD1 was incubated for 30 minutes in exchange buffer with
5% DMSO (squares) or 5% DMSO containing 100 µM NPPD (lozenges). 0.3 µM [3H]-
GDP loaded RhoG and 1 mM GTP were then added and the amount of radioactivity
associated with RhoG was measured after 0, 1, 2, 5, 10 and 15 minutes. As a
control, [3H]-GDP loaded RhoG was incubated alone in exchange buffer containing 1
mM GTP and 5% DMSO (triangles).
Figure 4: Analysis of TRIO-GEFD1 inhibition by NPPD, PEPD and CPEPD.
In vitro exchange assays were performed by measuring the increase in fluorescence
emitted with time upon incorporation of Mant-GTP into RhoG. A: Structure of 1,1'-
(1,2-phenylene)bis(1H-pyrrole-2,5-dione) (PEPD, a) and 1,1'-(2-chloro-1,4-
phenylene)bis(1H-pyrrole-2,5-dione) (CPEPD, b). B: 0.1 µM TRIO-GEFD1 was
incubated with 1 µM RhoG in the presence of NPPD (a), CPEPD (b) and PEPD (c) at
0 µM (DMSO), 25 µM, 50 µM and 100 µM. (d) Kobs, inhibition of the exchange
reactions shown in a-c and IC50 of the compounds.
Figure 5: Analysis of NPPD, PEPD and CPEPD specificity. In vitro exchange
assays were performed by measuring the amount in fluorescence emitted with time
upon binding of Mant-GTP into RhoG. A: 1 µM of Mant-GTP loaded RhoG was
incubated alone (DMSO in a-c) or with 100 µM NPPD (a), CPEPD (b) or PEPD (c) or
with the exchange factor (TRIO-GEFD1 in a-c). B: 1 µM RhoA was incubated alone
(no GEF, a-c) or with 0.1 µM ARHGEF17 alone (DMSO in a-c) or in the presence
NPPD (a), CPEPD (b) and PEPD (b) at 100 µM, corresponding to a 1000 fold molar
excess compared to the exchange factor. C: 1 µM Arf1 was incubated alone (no
GEF, a-c) or with 0.02 µM ARNO alone (DMSO in a-c) or in the presence NPPD (a),
CPEPD (b) and PEPD (b) at 20 µM, corresponding to a 1000 fold molar excess
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compared to the exchange factor. D: Kobs and inhibition of the exchange reactions
shown in B (RhoA+ARHGEF17) and C (Arf1+ARNO).
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